Quoin pharmaceuticals provides corporate update and reports fourth quarter and full-year 2024 financial results

Ashburn, va., march 13, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the "company" or "quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress.
QNRX Ratings Summary
QNRX Quant Ranking